Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303290 | 1.00 | AGTR2 (0.39) | AGTR2OPRM1OPRD1OPRK1BDKRB2 | |
| SCHEMBL4292542 | 0.90 | ABCB1 (0.47) | AGTR2OPRM1OPRD1OPRK1NR1D1 | |
| SCHEMBL30207112 | 0.90 | ABCB1 (0.47) | AGTR2OPRM1OPRD1OPRK1NR1D1 | |
| SCHEMBL4299042 | 0.84 | ABHD6 (0.36) | NR1D1ABHD6DAGLA | |
| SCHEMBL13662023 | 0.84 | TAAR1 (0.36) | AGTR2TAAR1LMNA | |
| SCHEMBL4297705 | 0.83 | NPC1 (0.40) | LMNA | |
| SCHEMBL4292430 | 0.83 | PPM1D (0.34) | — | |
| SCHEMBL21272076 | 0.83 | ABCB1 (0.50) | OPRM1ABCB1LMNA | |
| SCHEMBL21272093 | 0.83 | ABCB1 (0.50) | OPRM1ABCB1LMNA | |
| SCHEMBL14348092 | 0.82 | ABCB1 (0.42) | AGTR2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3841086-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020041301-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | AGTR2 239/4885OPRM1 4116/4885OPRD1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.